Updated guidelines outlining the requirements for obtaining authorisation to prescribe or supply psychostimulants for ADHD in children, adolescents and adults have been released. These guidelines have been revised to align with the release of new authority application forms and can be accessed on the NSW Health website or from the links below
Criteria for the Management of Medication for Attention Deficit Hyperactivity Disorder in Children and Adolescents (TG181)
Criteria for the Management of Medication for Attention Deficit Hyperactivity Disorder in Adults (TG190)
From 1 November 2022 all prescriptions for Schedule 4 and Schedule 8 medicines, including handwritten and computer-generated prescriptions, must include the patient’s date of birth. The dispensing pharmacist must make a record of the date of birth in the dispensing system when dispensing the medicine.
special temporary authority to allow the pharmacist to supply prescription medicines (other than Schedule 4 Appendix D and Schedule 8 medicines) during the COVID-19 pandemic is in place until 1 February 2023.
supply of prescription medicines for valid prescription formats.
On 13 November 2022, the NSW Government
announced its commitment to:
Consumers require a prescription to be supplied with nicotine vaping products, such as nicotine e-cigarettes, nicotine pods and liquid nicotine.
The TGA has not approved any nicotine vaping products for supply in Australia. Pathways for access to these unapproved therapeutic goods are the:
For more information, refer to
In some circumstances it is legal for a retail pharmacist to substitute different strengths or formulations of a prescribed medicine, without contacting the prescriber.
Where there is a Serious Scarcity Substitution Notice on the
TGA website, substitution is permitted if it is appropriate and the patient consents. The notice will specify which products may be substituted and the specific circumstances it may be substituted.
Under Part 4A of the NSW Poisons and Therapeutic Goods Act 1966, pharmacists must comply with all provisions of the relevant Commonwealth Serious Scarcity and Substitutable Medicine Instrument.
For information on subsidy under the Commonwealth Pharmaceutical Benefits Scheme, visit the
NSW is participating in the
Australian Government take home naloxone pilot which supplies take home naloxone
free of charge to people who may experience, or witness, an opioid overdose.
Nyxoid® nasal spray and Prenoxad® pre-filled syringe are available for free without a prescription at:
Outside of the pilot, naloxone is also available on a doctor's prescription or over the counter from a community pharmacist.
The Commonwealth PBS transitional arrangements for use of an electronic National Residential Medication Chart (eNRMC) is under the National Health (Electronic National Residential Medication Chart Trial) Special Arrangement 2018. Only the residential care facilities (RCF) and community pharmacies in the Schedule of the Special Arrangement may use the respective eNRMC in the Schedule.
Use of the eNRMC must comply with the
National Health (Electronic National Residential Medication Chart Trial) Special Arrangement 2018. Only the RCFs and community pharmacies in the Schedule of the Special Arrangement may use an eNRMC.
exemptions to the NSW Poisons and Therapeutic Goods Regulation 2008 electronic prescribing on an eNRMC can be used:
This applies to all medicines prescribed for RCF residents (that is, PBS and non-PBS).